Clinical Trial: An Exploratory Study of Sintilimab Combined with CAPOX for Initially Unresectable High-Risk Locally Advanced Rectal Cancer Patients with Proficient Mismatch Repair and/or Microsatellite Stable Status (China)

China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'An Exploratory Study of Sintilimab Combined with CAPOX for Initially Unresectable High-Risk Locally Advanced Rectal Cancer Patients with Proficient Mismatch Repair and/or Microsatellite Stable Status'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129426

Registration Time: 2026/08/04

Type: Interventional study

Primary Sponsor: harbin medical university cancer hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=334809

Published by HT Digital Content Services with permission from Health Daily Digest....